Clinical research with medical devices indicated in accordance with the CE marking, led by researchers, multicenter, open, prospective, randomized and controlled. Patients are randomized to treatment with a conventional balloon and then a coronary stent or to initial plaque modification with Orbital Atherectomy (OA) and then a coronary stent. To evaluate the efficacy and safety of OA in the adequate treatment with coronary stent of the calcified bifurcation lesion using angiography and optical coherence tomography (OCT).
The risk profile of patients and their comorbidities have worsened and the observed lesions undergoing treatment are increasingly complex. This has promoted the development of new technologies for plaque modification, especially in the context of calcified lesions. These predispose to suboptimal results of the intervention due to an increased risk of malapposition and underexpansion of the stents, the main variables for restenosis and/or thrombosis of the stents. Thus, compared with non-calcified lesions, the increased amount of calcium in the coronary artery leads to a higher incidence of major adverse cardiac events (MACE). Coronary bifurcation stenting remains complex and is associated with a high risk of stent thrombosis and restenosis even with contemporary techniques, and suboptimal outcomes are frequently observed due to side branch (SL) involvement that increases cardiovascular events. Our hypothesis is that the use of orbital atherectomy (OA) for coronary revascularization in the presence of calcified bifurcation lesions is feasible and safe compared to the more common technique, favoring the subsequent performance of provisional stenting (PS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.
Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.
H. G.U. de ALICANTE DR. BALMIS
Alicante, Spain
RECRUITINGHospital Universitario Lucus Augusti
Lugo, Spain
RECRUITINGHospital Universitario La Luz
Madrid, Spain
RECRUITINGEFFICACY: Angiographic criteria success
Percentage of Main vessel and side branch (≥2 mm) patency (final stenosis \<20%) without the presence of: residual lesion \>70% and TIMI flow \< 3 and residual ≥ type C disection
Time frame: At the end of PCI (Percutaneous Coronary Intervention)
EFFICACY: OCT criteria: Stent expansion
Percentage of MLA / mean reference luminal area (mean proximal and distal reference luminal)
Time frame: At the end of PCI
SAFETY:Major adverse cardiac events (MACE)
Rate of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and non-target lesion target vessel revascularization (TVR non-TLR), thrombosis and stroke
Time frame: 12 months
SAFETY:Major adverse cardiac events (MACE)
Rate of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and non-target lesion target vessel revascularization (TVR non-TLR), thrombosis and stroke
Time frame: 6 months
SAFETY:Major adverse cardiac events (MACE)
Rate of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and non-target lesion target vessel revascularization (TVR non-TLR), thrombosis and stroke
Time frame: 30 days
SAFETY:Major adverse cardiac events (MACE)
Rate of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), and non-target lesion target vessel revascularization (TVR non-TLR), thrombosis and stroke
Time frame: At the end of PCI
EFFICACY: Other variables related to stent expansion. Minimal Lumen Area (MLA) in mm2
Cut-off point \>5 mm2
Time frame: At the end of PCI
EFFICACY: Other variables related to stent expansion. Minimal Lumen Area (MLA)
Percentage of Cut-off point \>90 mm2
Time frame: At the end of PCI
EFFICACY: Other variables related to stent expansion. Mean stent expansion
Percentage of mean stent area (sum of stent area/analyzed stent length)/mean reference lumen area (cut-off point\>80%)
Time frame: At the end of PCI
EFFICACY: Other variables related to stent expansion. Stent expansion using linear model
Percentage of stent volume/adaptative reference lumen volume. (cut-off point\>65%)
Time frame: At the end of PCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.